Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

HER-2 expression + HER-2 D769H

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

HER-2 positive (332)

HER-2 overexpression (132)

HER-2 negative (120)

HER-2 expression (87)

HER-2 underexpression (38)

HER-2 negative + PD-L1 expression (12)

HR positive + HER-2 negative (5)

HER-2 positive + PD-L1 expression (3)

CD47 positive + HER-2 positive (2)

CLDN18.2 expression + HER-2 negative (2)

CLDN18.2 positive + HER-2 negative (2)

EGFR overexpression + HER-2 overexpression (2)

ER positive + HER-2 negative (2)

FGFR2b overexpression + HER-2 negative (2)

HR positive + HER-2 underexpression (2)

PD-L1 expression + HER-2 overexpression (2)

CEACAM6 positive + HER-2 positive (1)

EGFR expression + HER-2 expression (1)

ER negative + HER-2 negative (1)

ER positive + PGR negative + HER-2 negative (1)

HER-2 positive + CAV1 overexpression (1)

HER-2 underexpression + ER underexpression (1)

HR positive + HER-2 positive (1)

MET expression + HER-2 expression (1)

MET overexpression + HER-2 overexpression (1)

TPBG underexpression + HER-2 overexpression (1)

TROP2 expression + HER-2 underexpression (1)

ER negative + HER-2 positive (0)

ER positive + HER-2 positive (0)

ER positive + PGR positive + HER-2 positive (0)

HER-2 amplification + HR-positive (0)

HER-2 negative + AR positive + ER positive (0)

HER-2 negative + CLDN18.2 positive (0)

HER-2 negative + ER positive (0)

HER-2 negative + FGFR2b overexpression (0)

HER-2 negative + HR negative (0)

HER-2 negative + HR negative + PD-L1 expression (0)

HER-2 negative + PGR positive (0)

HER-2 overexpression + HR negative (0)

HER-2 overexpression + HR positive (0)

HER-2 positive + HER-2 overexpression (0)

HER-2 positive + HR negative (0)

HER-2 positive + RAS wild-type (0)

HR negative + HER-2 positive (0)

PD-L1 expression + HER-2 expression (0)

PGR positive + HER-2 positive (0)

HER-2 positive (332)

HER-2 overexpression (132)

HER-2 negative (120)

HER-2 expression (87)

HER-2 underexpression (38)

HER-2 negative + PD-L1 expression (12)

HR positive + HER-2 negative (5)

HER-2 positive + PD-L1 expression (3)

CD47 positive + HER-2 positive (2)

CLDN18.2 expression + HER-2 negative (2)

CLDN18.2 positive + HER-2 negative (2)

EGFR overexpression + HER-2 overexpression (2)

ER positive + HER-2 negative (2)

FGFR2b overexpression + HER-2 negative (2)

HR positive + HER-2 underexpression (2)

PD-L1 expression + HER-2 overexpression (2)

CEACAM6 positive + HER-2 positive (1)

EGFR expression + HER-2 expression (1)

ER negative + HER-2 negative (1)

ER positive + PGR negative + HER-2 negative (1)

HER-2 positive + CAV1 overexpression (1)

HER-2 underexpression + ER underexpression (1)

HR positive + HER-2 positive (1)

MET expression + HER-2 expression (1)

MET overexpression + HER-2 overexpression (1)

TPBG underexpression + HER-2 overexpression (1)

TROP2 expression + HER-2 underexpression (1)

ER negative + HER-2 positive (0)

ER positive + HER-2 positive (0)

ER positive + PGR positive + HER-2 positive (0)

HER-2 amplification + HR-positive (0)

HER-2 negative + AR positive + ER positive (0)

HER-2 negative + CLDN18.2 positive (0)

HER-2 negative + ER positive (0)

HER-2 negative + FGFR2b overexpression (0)

HER-2 negative + HR negative (0)

HER-2 negative + HR negative + PD-L1 expression (0)

HER-2 negative + PGR positive (0)

HER-2 overexpression + HR negative (0)

HER-2 overexpression + HR positive (0)

HER-2 positive + HER-2 overexpression (0)

HER-2 positive + HR negative (0)

HER-2 positive + RAS wild-type (0)

HR negative + HER-2 positive (0)

PD-L1 expression + HER-2 expression (0)

PGR positive + HER-2 positive (0)

›

HER-2 expression + HER-2 D769H	Gastric Cancer	HER-2 expression + HER-2 D769H	Gastric Cancer	pembrolizumab + trastuzumab Resistant: C3 – Early Trials pembrolizumab + trastuzumab Resistant : C3	pembrolizumab + trastuzumab Resistant: C3 – Early Trials pembrolizumab + trastuzumab Resistant : C3
HER-2 expression + HER-2 D769H	Gastroesophageal Junction Adenocarcinoma	HER-2 expression + HER-2 D769H	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + trastuzumab Resistant: C3 – Early Trials pembrolizumab + trastuzumab Resistant : C3	pembrolizumab + trastuzumab Resistant: C3 – Early Trials pembrolizumab + trastuzumab Resistant : C3